Abstract Number: 1479 • ACR Convergence 2022
Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample
Background/Purpose: Neuromyelitis Optica (NMO), also known as Devic's disease, is a rare inflammatory demyelinating disorder causing myelitis and optic neuritis. While there have been reports…Abstract Number: 1464 • ACR Convergence 2022
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…Abstract Number: 1478 • ACR Convergence 2022
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
Background/Purpose: T cells play a critical role in the pathogenicity of SLE and lupus nephritis (LN). Hence, identifying T cell co-stimulatory pathways and mediators that…Abstract Number: 1477 • ACR Convergence 2022
Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years
Background/Purpose: To study the prevalence and risk factors of fragility fractures in a longitudinal cohort of patients with SLE.Methods: All patients who fulfilled ≥4 1997…Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…Abstract Number: 1423 • ACR Convergence 2022
Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with…Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…Abstract Number: 1469 • ACR Convergence 2022
Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher prevalence and incidence of herpes zoster (HZ) compared with the general population. Our study was…Abstract Number: 1371 • ACR Convergence 2022
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…Abstract Number: 1480 • ACR Convergence 2022
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Background/Purpose: Kidney disease is a common manifestation of systemic lupus erythematosus (SLE); when it presents as glomerulonephritis also known as lupus nephritis (LN), it predicts…Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…Abstract Number: 1444 • ACR Convergence 2022
Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) had a higher risk of pericarditis, which could be life-threating, but there has been no research focusing on…
- « Previous Page
- 1
- …
- 381
- 382
- 383
- 384
- 385
- …
- 2425
- Next Page »